SCHEMBL2522754

SCHEMBL2522754

Cc1nc(C2=CC[C@@H](C(=O)NN)CC2)cs1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.45
NPC1 O15118 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
ABL1 P00519 1/20 0.39
KDM4E B2RXH2 4/20 0.39
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
ALDH1A1 P00352 4/20 0.34
ECE1 P42892 2/20 0.34
PKM P14618 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
KDM4A O75164 1/20 0.33
KDM4B O94953 1/20 0.33
KDM5C P41229 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2522752 1.00 RAB9A (0.45) RAB9ANPC1SMN1; SMN2ABL1KDM4E
SCHEMBL2524482 0.84 RAB9A (0.43) RAB9ANPC1SMN1; SMN2ABL1KDM4E
SCHEMBL2524485 0.84 RAB9A (0.43) RAB9ANPC1SMN1; SMN2ABL1KDM4E
SCHEMBL2517575 0.79 TSHR (0.47) RAB9ANPC1SMN1; SMN2MAPTGAA
SCHEMBL2517577 0.79 TSHR (0.47) RAB9ANPC1SMN1; SMN2MAPTGAA
SCHEMBL2588355 0.72 RAB9A (0.50) RAB9ANPC1SMN1; SMN2ABL1KDM4E
SCHEMBL2588353 0.72 RAB9A (0.50) RAB9ANPC1SMN1; SMN2ABL1KDM4E
SCHEMBL2527562 0.72 ADORA2A (0.42) RAB9ANPC1SMN1; SMN2ABL1MAPT
SCHEMBL2527559 0.72 ADORA2A (0.42) RAB9ANPC1SMN1; SMN2ABL1MAPT
SCHEMBL15047223 0.72 LMNA (0.53) RAB9ANPC1SMN1; SMN2MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558467-B1 ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2017-05-17 EP disclosed
US-8461151-B2 Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes HOFFMANN-LA ROCHE INC. (US) 2013-06-11 US disclosed
EP-2558467-A1 ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E]AZULENES AS VASOPRESSIN ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2013-02-20 EP disclosed
WO-2011128265-A1 ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E] AZULENES AS VASOPRESSIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-10-20 WO disclosed
US-20110251183-A1 ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES F. HOFFMANN-LA ROCHE AG (CH) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251183-A1 ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES OXTR, AVPR1B, AVPR1A RAB9A 1034/4885NPC1 1309/4885SMN1; SMN2 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.